Twist Bioscience Director Executes 18,417‑Share Buy‑Sell Combo, Balancing Executive Sell‑offs and Betting on Short‑Term Upside

Insider Activity Spotlight: Twist Bioscience Corp.

Twist Bioscience’s recent Form 4 filing from owner Chess Robert shows a Rule 10b‑5‑1 trading plan in full swing. On August 7 the director executed a simultaneous buy of 18,417 shares at $11.89 and a sell of 18,417 shares at $110.89, leaving him with 39,501 shares. The plan, adopted May 8, was designed to offset the large block of stock that the company’s executives have been selling. The timing—just two days after a 0.01 % drop in the stock and amid a 393 % surge in social‑media buzz—suggests Chess is using the plan to capture a short‑term upside while maintaining a long‑term stake.

What Investors Should Take Note Of

1. Signal of Confidence The buy at the low end of the trading plan’s range indicates Chess believes the stock is undervalued relative to his purchase price, which is well below the current $124.88 close. His post‑transaction holding of ~39.5 k shares represents a sizeable portion of his equity, reinforcing a long‑term commitment.

2. Counterbalance to Executive Sell‑offs The company’s leadership, especially COO Finn John and CEO Emily Leproust, have been selling sizable blocks in recent weeks (e.g., $110.89 sale by Chess). Chess’s buy offsets these outflows, potentially smoothing volatility and signaling that insiders are still bullish on the company’s biotech pipeline.

3. Strategic Timing with Market Momentum The transaction coincides with a 36 % monthly rise and 329 % yearly gain, indicating robust market sentiment. Chess’s purchase, coupled with his sale, may be an effort to lock in gains while keeping a stake as the company approaches its $125.66 52‑week high.

Chess Robert: A Profile Through History

Chess’s insider history shows a pattern of disciplined trading via Rule 10b‑5‑1 plans. He has repeatedly bought and sold identical share blocks, a strategy that reduces market impact and mitigates insider‑trading accusations. His holdings have fluctuated between 42,528 shares (pre‑plan) and 39,501 shares (post‑transaction), indicating he is comfortable adjusting exposure. Unlike some executives who trade on market timing, Chess’s consistent use of a trading plan suggests a focus on long‑term value creation rather than short‑term speculation.

Implications for the Company’s Future

The combined insider activity paints a nuanced picture: executives are liquidating to fund other ventures or diversify holdings, while Chess remains invested. His trade could be interpreted as a hedge against potential short‑term price swings, especially given the company’s high price‑to‑earnings ratio of –52.02 and a negative earnings environment. The continued insider participation, despite heavy selling, signals confidence in the company’s synthetic DNA platforms and its path toward new therapies and data‑storage solutions. For investors, Chess’s disciplined plan and the broader insider trend suggest that the stock’s upward trajectory is likely to continue, provided the company delivers on its research milestones and regulatory approvals.